Therapeutics for B-cell non-Hodgkin lymphoma (B-NHL) have advanced over recent decades, with immunotherapies taking a central role in the evolving treatment paradigm. Bispecific antibodies (bsAbs) that engage T cells (via CD3) and malignant B cells (via CD20), including four CD20×CD3 bsAbs (mosunet...
Page:
of
19